Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11636658 | 0.90 | LMNA (0.61) | GAAMAPTPOLBKMT2AUSP2 | |
| SCHEMBL11638476 | 0.89 | GAA (0.71) | GAAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL11638474 | 0.84 | GAA (0.63) | GAAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL11642724 | 0.83 | MAPT (0.56) | GAAMAPTPOLBKMT2AUSP2 | |
| SCHEMBL11626342 | 0.82 | HPSE (0.72) | GAAMAPTPOLBSMN1; SMN2KDM4E | |
| SCHEMBL3102305 | 0.81 | GAA (1.00) | GAAPOLBKMT2AMEN1KDM4E | |
| Methane SCHEMBL505763 | 0.81 | HPSE (0.70) | GAAMAPTPOLBSMN1; SMN2KDM4E | |
| SCHEMBL7238282 | 0.80 | GAA (0.65) | GAAKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL9074105 | 0.80 | AKR1B1 (0.58) | GAAMAPTPOLBKMT2ATSHR | |
| Methane SCHEMBL25304065 | 0.80 | HPSE (0.69) | MAPTPOLBSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | claimed |
| US-4100168-A | ANALGESICS, ANTIPYRETIC, ANTIINFLAMMATORY AGENTS | LILLY INDUSTRIES LTD. (GB) | 1978-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | GRIA1, GRIA3, GRIA2 | GAA 793/4885MAPT 2292/4885POLB 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.